Regulation - Pricing, Inlyta

Filter

Current filters:

PricingInlyta

Popular Filters

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

UK’s NICE recommends Pfizer’s Inlyta for kidney cancer

16-12-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) has issued new…

InlytaOncologyPfizerPharmaceuticalPricingRegulationUK

UK’s NICE does U-turn on Pfizer’s Inlyta for advanced kidney cancer

UK’s NICE does U-turn on Pfizer’s Inlyta for advanced kidney cancer

04-03-2014

UK drug watchdog the National Institute for Health and Care Excellence (NICE) this morning published…

InlytaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

NICE denies NHS use of Pfizer's Inlyta for patients with terminal kidney cancer

28-03-2013

In a second disappointment from the agency this week, US drugs behemoth Pfizer (NYSE: PFE) Ltd expressed…

EuropeInlytaOncologyPfizerPharmaceuticalPricingRegulation

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

09-01-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit…

BayerEuropeInlytaNexavarOncologyPfizerPharmaceuticalPricingRegulation

COMPANY SPOTLIGHT

Menarini

Back to top